OneSource Accepts SVP Resignation Effective May 15

OneSource Specialty Pharma Limited has accepted the resignation of Prateek Gupta from his position as Senior Management Personnel. Gupta, who served as the Senior Vice President & Head – Technical Development, has been relieved from his duties effective the closing hours of May 15, 2026. The company submitted the acknowledgement copy of the resignation letter to the stock exchanges on May 18, 2026.

Resignation Details

The resignation follows an initial intimation dated May 13, 2026. The company confirmed the cessation in accordance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The key details of the change are outlined below:

Parameter	Details
Name	Prateek Gupta
Designation	SVP & Head – Technical Development
Category	Senior Management Personnel (SMP)
Reason for Change	Resignation
Date of Cessation	May 15, 2026

Regulatory Compliance

The disclosure was submitted on behalf of OneSource Specialty Pharma Limited by Trisha A, Company Secretary and Compliance Officer (Membership Number: A47635). The company confirmed that the brief profile and disclosure of relationship between directors are not applicable in this instance.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
-2.84%	-8.79%	-10.02%	-2.42%	-18.46%	-3.43%

OneSource Specialty Pharma Limited announced its audited standalone and consolidated financial results for the quarter and year ended March 31, 2026. The Board of Directors, meeting on May 13, 2026, approved the results and appointed B S R & Co. LLP as statutory auditors, replacing Deloitte Haskins & Sells. The company reported a strong sequential recovery in Q4FY26, with consolidated revenue rising 47% quarter-on-quarter to ₹4,282.17 million, driven by growth across all service offerings and the India semaglutide commercial launch. EBITDA for the quarter expanded to ₹919 million, with margins improving to 21%. However, for the full fiscal year FY26, the company reported a consolidated net loss of ₹738.03 million compared to a net loss of ₹172.81 million in the previous year.

Q4 Performance

The quarterly performance reflected significant operating leverage on higher Contract Service Agreement (CSA) revenues. Revenue for Q4FY26 was ₹4,282.17 million, up from ₹2,903.40 million in Q3FY26. EBITDA increased to ₹919 million from ₹173 million in the previous quarter. On a reported basis, PAT was ₹45.97 million, a turnaround from a loss of ₹886.99 million in Q3FY26. The company attributed the growth to successful semaglutide launches in India across multiple customer brands, alongside new launches in the US injectables and soft-gelatin businesses.

Metric (₹ million)	Q4FY26	Q3FY26	Q4FY25
Revenue	4,282.17	2,903.40	4,259.53
EBITDA	919	173	1,825
EBITDA Margin	21%	6%	43%
Reported PAT	45.97	(886.99)	991.92
Adjusted PAT	390	(472)	1,350
Adjusted EPS (₹)	3.4	(4.1)	12.2

Full-Year Financial Performance

For the full fiscal year FY26, consolidated revenue from operations stood at ₹14,215.90 million, a marginal decline from ₹14,448.53 million in FY25. The company reported a consolidated net loss of ₹738.03 million for FY26, compared to a net loss of ₹172.81 million in the previous year. Adjusted PAT for the year was ₹739 million, with an adjusted EPS of ₹6.5, compared to ₹21.0 in FY25. The decline in full-year profitability was attributed to a softer second half impacted by delayed semaglutide approvals in Canada and an elevated cost base due to the ramp-up of the DDC facility.

Metric (₹ million)	FY26	FY25
Revenue from Operations	14,215.90	14,448.53
EBITDA	3,042	4,665
EBITDA Margin	21%	32%
Reported Net Loss	(738.03)	(172.81)
Adjusted PAT	739	2,314
Adjusted EPS (₹)	6.5	21.0

Standalone Financial Highlights

On a standalone basis, revenue from operations for Q4FY26 was ₹4,189.62 million, compared to ₹2,902.20 million in Q3FY26 and ₹4,774.14 million in Q4FY25. Standalone profit after tax for Q4FY26 was ₹214.79 million, a turnaround from a loss of ₹621.85 million in Q3FY26. For the full year, standalone revenue from operations stood at ₹14,053.81 million versus ₹12,995.89 million in FY25, with standalone profit after tax of ₹212.10 million compared to ₹200.00 million in FY25.

Standalone Metric (₹ million)	Q4FY26	Q3FY26	Q4FY25
Revenue from Operations	4,189.62	2,902.20	4,774.14
Profit/(Loss) Before Tax	198.09	(550.95)	1,748.77
Profit/(Loss) After Tax	214.79	(621.85)	1,748.77

Standalone Metric (₹ million)	FY26	FY25
Revenue from Operations	14,053.81	12,995.89
Profit/(Loss) After Tax	212.10	200.00
Basic EPS (₹) – Continuing Ops	1.85	1.81

Auditor Appointment

The Board approved the appointment of B S R & Co. LLP (Firm's Registration No.: 101248W/W-100022) as the statutory auditors of the company, to hold office from the conclusion of the 19th Annual General Meeting for a term of five consecutive years, subject to shareholder approval. This replaces Deloitte Haskins & Sells (Firm Registration No. 008072S), whose term is ending at the ensuing annual general meeting. Deloitte Haskins & Sells issued an unmodified opinion on the audited financial results for the year ended March 31, 2026 and an unmodified conclusion in respect of the limited review for the quarter ended March 31, 2026.

Auditor Appointment Details	Particulars
Incoming Auditor	B S R & Co. LLP
Firm Registration No.	101248W/W-100022
Effective Date	From conclusion of 19th AGM
Term	Five consecutive years (until conclusion of 24th AGM)
Outgoing Auditor	Deloitte Haskins & Sells (Firm Reg. No. 008072S)
Subject to	Shareholder approval

Regulatory Filing

In compliance with Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, OneSource Specialty Pharma published a newspaper advertisement on May 14, 2026 in the Financial Express and Lokmat. The advertisement provided an extract of the audited financial results for the quarter and financial year ended March 31, 2026.